POC                                                 melanoma(105)
 _________________________________________________________________
  procarbazine.... 100 mg/sqm/day (maximum single dose 150 mg) 
                   orally from day 1 to day 10.
  vincristine..... 1.4 mg/sqm (maximum single dose 2 mg) IV on day 
                   1 and day 8.
  lomustine....... 150 mg/sqm (maximum single dose 200 mg) orally 
                   on day 1.
  FREQUENCY....... Repeat cycle every 4 to 6 weeks.

  reference...
    Carmo-Pereira J.  Costa FO.  Henriques E. Combination 
    cytotoxic chemotherapy with procarbazine, vincristine, and 
    lomustine (POC) in disseminated malignant melanoma: 8 years' 
    follow-up. Cancer Treatment Reports.  68(10):1211-4, 1984 Oct. 
  abstract...
    Forty-four consecutive ambulatory patients (24 male, 20 
    female; median age, 56 years [range, 21-76]) with evaluable 
    disseminated malignant melanoma (stages III/IV) were entered 
    in this study from October 1, 1975, to July 21, 1980 (last 
    follow-up, October 31, 1983); they were treated with 
    procarbazine (100 mg/,m2 orally; maximum dose, 150 mg) on Days 
    1-10, vincristine (1.4 mg/m2 iv; maximum dose, 2 mg) on Days 1 
    and 8, and lomustine (150 mg/m2 orally; maximum dose, 200 mg) 
    on Day 1, repeated every 4-6 weeks. Twenty-one patients (48%) 
    showed objective responses; 11 of these (25%) were complete 
    responses. Nine patients had received previous chemotherapy, 
    but none were treated with the drugs used in this protocol. 
    Responses were seen mainly in cutaneous and/or nodal sites and 
    pulmonary metastases. The median duration of remission was 10 
    months and the median survival of responders was 21 months 
    compared to 5 months for nonresponders. Four responding 
    patients are still alive and in complete response for 70+, 
    83+, 94+, and 95+ months, while one is alive, but in 
    progression (83+ months). The toxicity of this regimen was 
    clinically tolerable and hospitalization was not required. In 
    our initial study the response rate was 60% (18 responses 
    among 30 patients) and this regimen continues to have 
    significant antitumor activity against disseminated malignant 
    melanoma.